Deucravacitinib improved psoriatic arthritis over placebo, with low adverse event rates to 52 weeks

Design

Phase 3, randomised, double-blind, placebo-controlled trial, 52 weeks

Population

670 biologic-naive adults with active psoriatic arthritis

Primary outcome

ACR20 response at week 16

Effect

54.2% vs 34.1% (p<0.001); serious adverse events 1.8% vs 2.4%

The phase 3 POETYK PsA-1 trial randomised 670 adults with active psoriatic arthritis, naive to biologics, with raised CRP and at least one erosion, to oral deucravacitinib 6 mg daily, a selective tyrosine kinase 2 (TYK2) inhibitor, or placebo for 16 weeks, after which all received the active drug to week 52.

At 16 weeks, 54.2% on deucravacitinib achieved an ACR20 response against 34.1% on placebo. Responses increased by week 52, and those switched from placebo caught up. Radiographic progression was inhibited at 16 and 52 weeks on a post hoc analysis. Serious adverse events (1.8% vs 2.4%) and withdrawals for adverse events were low, with no imbalance in cardiovascular events, cancers or opportunistic infections.

ACR20 is a modest response threshold, the placebo-controlled phase lasted only 16 weeks, and there is no head-to-head comparison with established biologics or JAK inhibitors. The drug adds an oral option with a different mechanism; its regulatory status and cost in India for psoriatic arthritis are not addressed here. It was published in August 2026.

• Deucravacitinib is an oral TYK2 inhibitor that improved psoriatic arthritis over placebo in biologic-naive patients.
• About one in five more patients reached ACR20 than on placebo at 16 weeks.
• Serious adverse events were low and similar to placebo in this trial.
• There is no head-to-head evidence against biologics or JAK inhibitors yet.
• Check local regulatory approval for psoriatic arthritis before considering it.

Why it matters

An oral drug with a different safety profile would widen choice for patients who cannot use injections.

Don't overread it

The structural damage result came from a post hoc analysis, and ACR20 is a low bar.

The statistics, in plain English

A 20-point difference in ACR20 response means about one extra responder for every five patients treated. The comparison with placebo lasted only 16 weeks; after that, everyone received the drug, so longer-term data show durability, not comparative benefit.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.